<DOC>
	<DOCNO>NCT00085124</DOCNO>
	<brief_summary>This randomized phase III trial study daunorubicin , cytarabine , oblimersen see well work compare daunorubicin cytarabine treat old patient previously untreated acute myeloid leukemia . Drugs use chemotherapy , daunorubicin cytarabine , work different way stop cancer cell divide stop grow die . Oblimersen may increase effectiveness daunorubicin cytarabine make cancer cell sensitive drug . It yet know whether daunorubicin cytarabine effective without oblimersen treat acute myeloid leukemia .</brief_summary>
	<brief_title>Daunorubicin Hydrochloride , Cytarabine Oblimersen Sodium Treating Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary I . Compare outcome , term overall survival , disease-free survival , event-free survival , complete response rate , old patient previously untreated acute myeloid leukemia treat daunorubicin cytarabine without oblimersen . Secondary I . Determine significance expression select Bcl-2 family member protein know modulated oblimersen ( e.g. , Bcl-2 ) potentially mediate resistance oblimersen ( e.g. , Bcl-XL Mcl-1 ) predict clinical outcome patient treat regimen . II . Correlate clinical outcome serial change level mRNA protein expression Bcl-2 , pro-apoptotic binding partner Bax , anti-apoptotic Bax-binding protein ( e.g. , Bcl-XL Mcl-1 ) patient treat regimen . III . Determine effect pre-treatment characteristic ( e.g. , morphology , cytogenetics , molecular feature , expression multidrug resistance molecule , functional assay drug efflux , prior myelodysplastic syndrome , age , white blood cell ) toxicity regimens outcomes patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . Arm I : Remission induction therapy : Patients receive oblimersen IV continuously day 1-10 , cytarabine IV continuously day 4-10 , daunorubicin IV day 4-6 . Patients achieve complete remission ( CR ) proceed consolidation therapy . Patients achieve CR receive second course induction therapy . Second remission induction therapy : Patients receive oblimersen IV continuously day 1-8 , cytarabine IV continuously day 4-8 , daunorubicin IV day 4-5 . Patients achieve CR proceed consolidation therapy . Consolidation therapy : Patients receive oblimersen IV continuously day 1-8 high-dose cytarabine IV 3 hour day 4-8 . Patients continue CR receive second course consolidation therapy . Arm II : Remission induction therapy : Patients receive cytarabine IV continuously day 1-7 daunorubicin IV day 1-3 . Patients achieve CR proceed consolidation therapy . Patients achieve CR receive second course induction therapy . Second remission induction therapy : Patients receive cytarabine IV continuously day 1-5 daunorubicin IV day 1 2 . Patients achieve CR proceed consolidation therapy . Consolidation therapy : Patients receive high-dose cytarabine IV 3 hour day 1-5 . Patients continue CR receive second course consolidation therapy . In arm , treatment continue absence disease progression , unacceptable toxicity , failure achieve CR 2 course remission induction therapy , presence leukemic cell cerebrospinal fluid , leukemic regrowth , relapse consolidation therapy . Patients follow every 2 month 2 year , every 3 month 2 year , annually 10 year . PROJECTED ACCRUAL : A total 500 patient ( 250 per treatment arm ) accrue study within 4.2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia No promyelocytic leukemia History antecedent myelodysplasia allow provided patient receive prior cytotoxic therapy myelodysplastic syndrome PRIOR CONCURRENT THERAPY : Biologic therapy Prior growth factor and/or cytokine support allow No concurrent routine prophylactic myeloid growth factor Chemotherapy No prior chemotherapy leukemia myelodysplasia except follow condition : Emergency leukapheresis Emergency treatment hyperleukocytosis hydroxyurea No concurrent chemotherapy Endocrine therapy No concurrent hormone except steroid adrenal failure hormone nondiseaserelated condition allow ( e.g. , insulin diabetes ) Radiotherapy Prior cranial radiotherapy CNS leukostasis ( 1 dose ) allow No concurrent palliative radiotherapy Surgery Not specify Other Concurrent enrollment CALGB8461 , CALGB9665 , CALGB9760 allow No concurrent investigational commercial agent therapy intend treat malignancy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>